Form 4: Entera Bio Ltd. Executive Hillel Galitzer Reports Stock and Option Transactions

Hillel Galitzer, Chief Operating Officer of Entera Bio Ltd., reports acquisition of restricted stock units and stock options, as well as disposal of ordinary shares.

Summary

• On April 19, 2024, Hillel Galitzer, the Chief Operating Officer of Entera Bio Ltd., reported transactions involving the company's securities.
• Galitzer acquired 30,151 ordinary shares through a grant of stock-settled restricted stock units at a price of $0 per share.
• These restricted stock units vest ratably on a quarterly basis over a one-year period starting April 19, 2024.
• Galitzer also acquired options to purchase 130,000 ordinary shares at an exercise price of $1.99.
• These options vest over a three-year period, with 33% vesting on April 19, 2025, and the remainder vesting ratably on a quarterly basis over the subsequent two years.
• Additionally, Galitzer disposed of 64,257 ordinary shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it primarily reports transactions by an officer, which is a routine occurrence. The acquisition of shares and options is balanced by the disposal of shares.

Positives

• The grant of restricted stock units and stock options to the COO could be seen as an incentive to align his interests with those of the shareholders.

Negatives

• The disposal of 64,257 ordinary shares by the COO could be interpreted negatively by some investors.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's securities. It's common for executives to receive stock options and restricted stock units as part of their compensation packages.

Stakeholder Impact

• Shareholders may be interested in the transactions of company insiders as an indicator of management's confidence in the company's future prospects.

Key Dates